Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371567 | 0.84 | CTSK (0.50) | CTSLCTSKCTSSTDP1ALDH1A1 | |
| SCHEMBL12370542 | 0.84 | CTSL (0.69) | CTSLCTSKKLK5CTSSKLK7 | |
| SCHEMBL12371562 | 0.81 | CTSL (0.50) | CTSLCTSKKMT2ADPP8DPP9 | |
| SCHEMBL18540645 | 0.81 | CTSL (0.75) | CTSLCTSKKLK5CTSSMAPT | |
| SCHEMBL13619474 | 0.74 | CTSL (0.76) | CTSLCTSKKLK5CTSSKLK7 | |
| SCHEMBL12372025 | 0.72 | CTSL (0.71) | CTSLCTSKTDP1ALDH1A1MAPT | |
| SCHEMBL23834171 | 0.71 | CTSK (0.48) | CTSK | |
| SCHEMBL23834169 | 0.71 | CTSK (0.48) | CTSK | |
| SCHEMBL23834366 | 0.71 | RIPK1 (0.47) | CTSKTDP1DPP8DPP9 | |
| SCHEMBL23834368 | 0.71 | RIPK1 (0.47) | CTSKTDP1DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-08-25 | — | — | US | disclosed |
| WO-2009136997-A2 | INHIBITORS OF HUMAN CATHEPSIN L, CATHEPSIN B, AND CATHEPSIN S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | CTSB, CTSS, CTSV | CTSL 7/4885CTSK 11/4885KLK5 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.